ChemoMetec A/S : Major shareholder announcement - AIM International Mutual Funds
March 18, 2024 at 07:30 am EDT
Share
Danish
English
Published: 2024-03-18 12:28:00 CET
ChemoMetec
Major shareholder announcements
Major shareholder announcement - AIM International Mutual Funds
ANNOUNCEMENT NO. 257
Major shareholder announcement
Major shareholder announcement - AIM International Mutual Funds
Pursuant to Section 30 of the Danish Capital Markets Act, it is hereby announced that Invesco Ltd. has informed ChemoMetec A/S that AIM International Mutual Funds (Invesco International Mutual Funds) on 13 March 2024, increased its holding of shares and voting rights to above 5% of the total share capital and voting rights in ChemoMetec A/S, and that the holding thus exceeds the 5 per cent limit in section 38 of the Capital Markets Act.
Additional information
Niels Høy Nielsen, CFO
Telephone (+45) 2551 8724
About ChemoMetec A/S
ChemoMetec develops, manufactures and markets instruments for cell counting and a wide range of other measurements. ChemoMetec's instruments are marketed to the pharmaceutical, biotech and agricultural industries worldwide. ChemoMetec's customers include some of the world's leading pharmaceutical companies, such as Novartis, Novo Nordisk, H. Lundbeck, Merck, AstraZeneca and Johnson & Johnson.
ChemoMetec was founded in 1997 and is listed on Nasdaq OMX Copenhagen. For more information, go towww.chemometec.com
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original Link
Permalink
Disclaimer
ChemoMetec A/S published this content on
18 March 2024 and is solely responsible for the information contained therein. Distributed by
Public, unedited and unaltered, on
18 March 2024 11:29:04 UTC.
Chemometec A/S is a Denmark-based company engaged in the development, manufacture and sale of analytical instruments used for quantitative analysis of cells in liquids. The Companyâs activities are divided into three business areas: Instruments, which offers a range of NucleoCounter analytical instruments for counting mammalian, animal, yeast and sperm cells, as well as somatic cells in milk, among others; Consumables, which distributes disposable cassettes, solutions, reagents and slides; and Other, which is responsible for the partnership development in a number of research projects, among others. The Companyâs analytical products are based on a technology, which combines fluorescence microscopy with digital imagery. Its customer portfolio comprises entities active primarily within pharmaceutical, food processing and agriculture industries. Furthermore, the Company is a parent of ChemoMetec USA Inc.
CHEMOMETEC A/S 
